| 3.36 -0.415 (-10.99%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.42 |
1-year : | 4.95 |
| Resists | First : | 3.78 |
Second : | 4.24 |
| Pivot price | 3.45 |
|||
| Supports | First : | 3.04 | Second : | 2.53 |
| MAs | MA(5) : | 3.5 |
MA(20) : | 3.49 |
| MA(100) : | 3.22  |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 52.1 |
D(3) : | 47 |
| RSI | RSI(14): 47 |
|||
| 52-week | High : | 11.55 | Low : | 1.47 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ARTV ] has closed above bottom band by 38.6%. Bollinger Bands are 45.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.8 - 3.83 | 3.83 - 3.85 |
| Low: | 3.29 - 3.31 | 3.31 - 3.33 |
| Close: | 3.33 - 3.36 | 3.36 - 3.39 |
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Mon, 17 Nov 2025
Aslan Fred sells Artiva Biotherapeutics (ARTV) stock for $21,522 - Investing.com
Wed, 12 Nov 2025
HC Wainwright & Co. Maintains Artiva Biotherapeutics (ARTV) Buy Recommendation - Nasdaq
Wed, 12 Nov 2025
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Wed, 12 Nov 2025
Artiva (NASDAQ: ARTV) reports no CRS/ICANS with AlloNK in 32 patients - Stock Titan
Sun, 19 Oct 2025
Artiva Biotherapeutics (ARTV) Is Up 113.9% After FDA Fast Track for AlloNK in Refractory RA – Has the Bull Case Changed? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 25 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 19.7 (%) |
| Held by Institutions | 74.3 (%) |
| Shares Short | 221 (K) |
| Shares Short P.Month | 204 (K) |
| EPS | -1.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.26 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.8 % |
| Return on Equity (ttm) | -48 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -77 (M) |
| Levered Free Cash Flow | -50 (M) |
| PE Ratio | -2.71 |
| PEG Ratio | 0 |
| Price to Book value | 0.63 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|